Pixalate Releases LATAM Q1 2024 Connected TV (CTV) Device Market Share Report: Roku Leads with 39% Market Share, Samsung No. 2 (35%)
May 02, 2024 16:15 ET
|
Pixalate Inc.
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Pixalate Releases Q1 2024 Global Connected TV (CTV) Device Market Share Report: Roku Leads with 48% Market Share, Samsung No. 2 (11%)
May 02, 2024 15:56 ET
|
Pixalate Inc.
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) Amplify Their Commitment to Nurturing Emerging Talent in Lung Cancer Research
May 02, 2024 08:00 ET
|
Lung Cancer Foundation of America
Los Angeles, CA, May 02, 2024 (GLOBE NEWSWIRE) -- In a significant stride towards unlocking the complexities of lung cancer that may lead to the next breakthrough treatment, Lung Cancer Foundation...
College Innovation Network Celebrates Four Years of Transformative Impact on Higher Education
May 02, 2024 08:00 ET
|
Western Governors University
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- The College Innovation Network (CIN), an initiative powered by WGU Labs and funded by the Charles Koch Foundation, today marked the completion of its...
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
May 02, 2024 07:30 ET
|
Bio-Gene Technology Co Ltd
Guangzhou Bio-gene Technologies announces the Initiation of a Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1 in patients with AML
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO
May 02, 2024 07:30 ET
|
Theratechnologies
Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solidesLa partie 3 de la phase I de l’essai sur le cancer...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024 07:30 ET
|
Theratechnologies
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL,...
Arvinas to Present at Upcoming Investor Conferences
May 02, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial
May 02, 2024 06:00 ET
|
Smart Immune
Smart Immune treats adult acute leukemia patient at final dose level in Phase I/II ReSET-02 trial PARIS, France, May 2, 2024 – Smart Immune, a clinical-stage biotechnology company developing...